Recent observations have raised the possibility of atypical fractures occurring in patients on long-term BMAs [89]; among patients with atypical fracture, the prevalence of bisphosphonate use was 90% [90]. Ongoing surveillance for atypical and minimal trauma fractures is warranted in patients undergoing therapy with BMAs.